Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.48 |
| ▸ | IGF2R | P11717 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.45 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984503 | 0.91 | LGALS8 (0.52) | CD69IGF2RMEN1KMT2ALGALS3 | |
| SCHEMBL17654900 | 0.89 | LGALS3 (0.49) | CD69IGF2RMEN1KMT2ALGALS3 | |
| SCHEMBL14616535 | 0.89 | LGALS3 (0.49) | CD69IGF2RMEN1KMT2ALGALS3 | |
| SCHEMBL14920478 | 0.89 | LGALS3 (0.47) | CD69IGF2RMEN1KMT2ALGALS3 | |
| SCHEMBL15720609 | 0.89 | LGALS3 (0.47) | CD69IGF2RMEN1KMT2ALGALS3 | |
| SCHEMBL12090483 | 0.88 | LGALS3 (0.56) | CD69IGF2RMEN1KMT2ALGALS3 | |
| SCHEMBL15709547 | 0.88 | LGALS3 (0.46) | CD69IGF2RMEN1KMT2ALGALS3 | |
| SCHEMBL15226769 | 0.88 | LGALS3 (0.46) | CD69IGF2RMEN1KMT2ALGALS3 | |
| SCHEMBL16588080 | 0.87 | CD69 (0.52) | CD69LGALS8PTPN1SLC28A3L3MBTL1 | |
| SCHEMBL16905359 | 0.87 | CD69 (0.52) | CD69LGALS8PTPN1SLC28A3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335851-A2 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | ImmunoGen, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3380525-B1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | IMMUNOGEN INC (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-115501172-A | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-12-23 | — | — | CN | disclosed |
| CN-107249570-B | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-08-09 | — | — | CN | disclosed |
| US-11278628-B2 | Pharmaceutical formulations and methods of use thereof | IMMUNOGEN, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20210230261-A1 | BUFFERED FORMULATIONS OF BEVACIZUMAB FOR USE OF TREATING DISEASES | OUTLOOK THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| CN-112543645-A | Buffered formulations of bevacizumab for treatment of disease | 前瞻疗法公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3781199-A1 | BUFFERED FORMULATIONS OF BEVACIZUMAB FOR USE OF TREATING DISEASES | Outlook Therapeutics, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3397281-B1 | BUFFERED FORMULATIONS OF BEVACIZUMAB | OUTLOOK THERAPEUTICS INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200222552-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | IMMUNOGEN, INC. | 2020-07-16 | — | — | US | disclosed |
| EP-1687012-A1 | STABILISATION OF VIRAL MICROPARTICLES | Quadrant Drug Delivery Limited (GB) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005053717-A1 | STABILISATION OF VIRAL MICROPARTICLES | QUADRANT DRUG DELIVERY LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| EP-0994887-B1 | MODIFIED GLYCOSIDES, COMPOSITIONS COMPRISED THEREOF AND METHODS OF USE THEREOF | ELAN DRUG DELIVERY LTD (GB) | 2002-11-27 | — | — | EP | disclosed |
| EP-0714905-B1 | Process for producing trehalose derivatives | HAYASHIBARA BIOCHEM LAB (JP) | 2002-04-03 | — | — | EP | disclosed |
| US-20020009464-A1 | Modified glycosides, compositions comprised thereof and methods of use thereof | ELAN DRUG DELIVERY LTD. (GB) | 2002-01-24 | — | — | US | disclosed |
| JP-2000204013-A | MAKE-UP COSMETIC WITHOUT DRYNESS | POLA CHEM IND INC | 2000-07-25 | — | — | JP | disclosed |
| EP-0994887-A2 | MODIFIED GLYCOSIDES, COMPOSITIONS COMPRISED THEREOF AND METHODS OF USE THEREOF | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 2000-04-26 | — | — | EP | disclosed |
| US-5906924-A | REACTING ANHYDROUS TREHALOSE UNDER ANHYDROUS CONDITIONS | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGUKU KENKYUJO (JP) | 1999-05-25 | — | — | US | disclosed |
| WO-1999001463-A2 | MODIFIED GLYCOSIDES, COMPOSITIONS COMPRISED THEREOF AND METHODS OF USE THEREOF | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1999-01-14 | — | — | WO | disclosed |
| EP-0714905-A2 | Process for producing trehalose derivatives | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278628-B2 | Pharmaceutical formulations and methods of use thereof | GABRA5, GABRA6, GABRA3 | CD69 2179/4885IGF2R 3889/4885MEN1 2741/4885 |
| US-20200222552-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE THEREOF | GABRA5, GABRA6, GABRA3 | CD69 2179/4885IGF2R 3889/4885MEN1 2741/4885 |
| US-20020009464-A1 | Modified glycosides, compositions comprised thereof and methods of use thereof | PYGM, GCG, PYGL | CD69 360/4885IGF2R 737/4885MEN1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.